Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-60 years of age~* Right-handed non-smokers~* Diagnosed with facial pain~* Continuous pain for more than 3 months~* Spontaneous pain greater than 3 of 10~* Allodynia to brush greater than 5 of 10~Exclusion Criteria:~* Medications~* Depression~* Significant medical problems~* Claustrophobia~* Abnormal EKG~* Significant drug or alcohol history~* Positive drug screen~* Weight greater than 285 lbs~* History of allergy to anticonvulsants~* Tattoos with metallic ink on upper body~* Any neurostimulator devices, or metal cochlear, ocular, or cardiac implants or other metal near vital areas~* Exposure to shrapnel or metal filings~* Other metallic surgical hardware

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lamotrigine to Placebo Crossover (Type: ACTIVE_COMPARATOR): The drug lamotrigine will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, placebo (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for placebo will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
- Placebo to Lamotrigine Crossover (Type: ACTIVE_COMPARATOR): The placebo will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, the drug lamotrigine (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for drug will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).